Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC.

Clinical lung cancer - 1 Jan 2026

Spira Alexander I, Berz David, Jotte Robert M, Pachipala Krishna K, Berger Mark S

Abstract excerpt

BACKGROUND: Expression of TUSC2, a tumor suppressor gene, is decreased in 82% of patients with NSCLC. Quaratusugene ozeplasmid gene therapy consists of a plasmid containing the TUSC2 gene encapsulated in lipid nanoparticles that restores TUSC2 expression, and thus is a new approach to cancer treatment. PATIENTS AND METHODS: Patients had NSCLC with EGFR mutations and progression on osimertinib regimens....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Genetic Therapy

Share to Indoles

Share to Lung Neoplasms

Share to Pyrimidines

Source

Identifiers

PMID: 41385873
DOI: 10.1016/j.cllc.2025.11.009

Genes

TUSC2
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC.PMID 41385873Read ↗

Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancerSemantic proximity Read ↗

Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients.Semantic proximity Read ↗

Re: Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancers.Semantic proximity Read ↗

Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.Semantic proximity Read ↗

Sitimagene Ceradenovec: A Gene-Based Drug for the Treatment of Operable High-Grade GliomaSemantic proximity Read ↗

Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.Semantic proximity Read ↗

Strategies of overcoming osimertinib resistance in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.